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Acute kidney injury in 
perioperative settings
ABSTRACT
Acute kidney injury is a clinical syndrome which represents relevant and serious perioperative complication. It is associated 
with increased patient morbidity, mortality, prolonged hospital stays, and not to mention greater healthcare costs. Yet, the 
patients who suffered from temporary acute kidney injury in the perioperative period, and regardless of the final outcome, 
usually complain afterwards about emotional distress, coupled with poor quality of life associated with loss of energy and 
limited normal physical activity.  Therefore, the role of the physician to predict a kidney vulnerable patient in the periope-
rative period is a task of great importance, albeit not an easy one. The key management is risk stratification of the patient 
in conjunction with hemodynamic and oxygen optimization, in addition to avoiding nephrotoxic agents during the entire 
perioperative period.
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Introduction
Acute kidney injury (AKI) in the periope-
rative period is a unique and common 
complication associated with a patient’s 
increased risk of morbidity, mortality, 
prolonged intensive care unit and hospi-
tal stays, as well as increased healthcare 
costs. (1-6) AKI usually occurs to 1% to 
5% of all hospitalized patients within the 
incidence of perioperative AKI varying 
between 1% and 25% dependent of the 
type of surgery and definition of AKI. (1,7) 
However, there are many studies about 
incidence, risk factors and pathophysio-
logical mechanisms of AKI emergence 
in patients submitted to cardiac and 
vascular surgery procedures, and those 
with preoperative pre-existing renal 
disease. But studies on incidence, risk 
factors and pathophysiological mecha-
nisms of AKI emergence in a population 
with preoperative normal renal function 
submitted for non-cardiac and non-vas-
cular general surgery procedures are 
still lacking. According to the studies, 1% 
of all patients with preoperative normal 
renal function submitted for a general 
surgical procedure have postoperative 
AKI. (8,9) Moreover, these studies show 
a three times higher risk in postoperative 
morbidity and a five times higher risk in 
postoperative mortality. (8) The periope-
rative period is characterized with cer-
tain hemodynamic derangements and 
insults that greatly impact the patient’s 
functional status. A careful and thorough 
evaluation of all organ systems and the 
patient’s functional status, together with 
an understanding of the type of surge-
ry and its requirements, can therefore 
help us create controlled conditions and 
apply early and optimal preventive trea-
tments and measures before deleterious 
renal insult occurs. (10,11)
Preoperative period
Risk stratification of the patient for 
perioperative AKI development is key 
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during the preoperative period.. The 
etiology of AKI is multi-factorial. (12) 
The risk factors for AKI development 
are patient-related, anaesthesia-rela-
ted and surgery-related. (12) Patient-
related risk factors include advanced 
age, male sex, higher body mass index, 
a Revised Cardiac Risk Index score 
greater than 2, an American Society of 
Anesthesiologists physical score of 4 
and 5, history of congestive heart dise-
ase, arterial hypertension, peripheral 
vascular disease, diabetes mellitus and 
a preoperative estimated glomerular fil-
tration rate less than 60 ml/min/1.73m2. 
(3,6,13-17) The Revised Cardiac Risk 
Index score (RCRI) was developed to 
predict major cardiac complications 
after non-cardiac surgery. (18,19) The 
RCRI score predicts perioperative car-
diac risk by assigning one point for 
the following six independent factors: 
high risk surgery (intrathoracic, intra-
peritoneal or suprainguinal vascular), 
ischemic heart disease, congestive 
heart disease, history of cerebrovascu-
lar disease, diabetes mellitus requiring 
insulin therapy and preoperative serum 
creatinine greater than 175 μmol/l. (18) 
The American Society of Anesthesiolo-
gists physical score (ASA-PS) classifi-
cation is a strong predictor for posto-
perative complication developments 
in patients in the perioperative period. 
(20). A study showed that higher ASA-
PS was associated with the emergence 
of AKI. (20) Anaesthesia-related risk 
factors include anaesthetic technique 
(spinal and epidural anaesthesia indu-
ce more pronounced hypotension), 
anaesthetic drugs, the intraoperati-
ve patient’s position associated with 
rhabdomyolysis, blood products admi-
nistration (especially a transfusion of 
erythrocytes older than 20 days), and 
intraoperative hemodynamic instability 
corrected with the use of inotropes and 
vasopressors. (21,22) Surgery-related 
risk factors include already mentioned 
high-risk surgery, prolonged surgery, 
type of surgery and the surgery’s spe-
cial requirements, such as aortic cross 
clamping, induced hypotension, pneu-
moperitoneum in laparoscopic surgery, 
and other specific surgical techniques. 
(23-25) Another important preopera-
tive strategy is to apply measures to 
enhance the patient’s cardiovascular 
and hemodynamic status by optimi-
sing blood pressure and fluid balance 
with crystalloid solutions, transfusion 
of blood products and albumins accor-
ding to the early goal directed therapy, 
review the patient’s drug list and the 
exclusion of nephrotoxic drugs, as well 
as consulting a nephrologist if doubts 
remain. (7)
Intraoperative period
The etiology of AKI is prerenal, renal 
and postrenal. In the perioperative peri-
od AKI is usually a consequence of pre-
renal and renal intrinsic cause. (7) The 
underlying mechanism of intraoperati-
ve AKI development is multi-factorial. 
However, the first and most important 
strategy is to maintain hemodynamic 
stability during surgery. The aim is to 
maintain both renal perfusion pressure 
and systemic arterial pressure that are 
appropriate for the individual patient 
and for the surgical requirements at 
the same time. (11) Aggressive fluid 
therapy is sometimes not enough 
to overcome the hypontension, and 
vasopressors must then be applied. 
According to recommendations, mean 
arterial pressure should be greater than 
65 mmHg and systolic blood pressure 
greater than 100 mmHg. (11) 
Because the outer kidney medulla has 
high metabolic and oxygen demands, 
it is necessary to maintain hemodyna-
mic stability with renal blood flow. (26). 
This makes the patient extremely vul-
nerable to hypoperfusion and hypoxia, 
especially patients with reduced renal 
reserves. (27-29) Another strategy is to 
prevent activation of the inflammation 
process associated with the surgery. 
However, every major surgery activa-
tes systemic inflammatory response 
syndrome in the organism which contri-
butes to AKI development by cell-medi-
ated and cytotoxic injury. (7,30) Also, 
hemolysis due to prolonged surgery 
with the excretion of the hem products 
contributes to renal tubular injury. (7) 
Moreover, avoiding the administration 
of nephrotoxic drugs during the surgi-
cal procedure can also minimize renal 
injury during this vulnerable period. In 
addition, ischemia-reperfusion injury 
in some surgeries presents a noxio-
us factor for the kidneys, as well as 
intraoperative tissues manipulation that 
contributes to embolic insult to the kid-
neys. (26)
Postoperative period
During the postoperative period, phar-
macological and non-pharmacological 
preventive measures must be applied 
in the risky patients. The aim of the 
treatment is optimising blood supply 
and oxygen delivery to the kidneys, 
minimizing demands and avoiding use 
of nephrotoxic drugs. (12) 
Optimizing blood supply 
and oxygen delivery
This measure is usually accomplished 
by maintaining the euvolemic patient 
and preserving renal autoregulation, 
which can be obtained by intravascular 
fluid administration, optimization and 
preservation of the patient’s cardiac 
function, and maintaining hemodyna-
mic stability. Recommendations state 
that crystalloid solutions and albumins 
can be used for intravascular volume 
replacement without fear of kidney 
damage. (7) The goal is to maintain 
mean arterial pressure greater than 
65 mmHg, and even higher for elderly 
and diabetic patients. (31) If the pati-
ent has an acceptable intravascular 
volume load and the mean arterial pre-
ssure value is not satisfactory, then 
first-line vasopressor noradrenalin can 
be implemented. This treatment is reco-
mmended for treating hypotension as 
it does not compromise renal, hepa-
tic or gastrointestinal blood flow. (7) 
Vasopresin and terlipressin can also be 
used to treat postoperative catechola-
mine resistant vasodilatatory shock. (7) 
Since blood loss is a reality of surgery, 
studies recommend that haemoglobin 
levels should be maintained up to 100 
g/l and hematocrit be greater than 21% 
to prevent perioperative renal ischemia 
and AKI. (12) Once all the factors are 
considered, it is evident that early goal 
directed therapy is the path that should 
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be persued as it involves using fluids, 
blood products and inotrope drugs to 
achieve target kidney protective physi-
ological values of hemodynamic para-
meters, such as cardiac output, car-
diac index and tissue oxygen delivery. 
(32,33)
Decreasing demands
The aim of this measure is to minimi-
ze the kidney’s, especially the outer 
medulla’s, metabolic rate and deman-
ds. One way to attain this is to sedate 
the patient. Another approach is the 
application of the loop diuretic furo-
semide. This reduces kidney oxygen 
demands by blocking the Na/K-ATP 
pump, which is a large energy consu-
mer. (12) By doing so, more energy is 
conserved for the ishemic kidney. (12) 
Equally, mannitol can be used to decre-
ase oxygen demands by increasing 
renal blood flow and scavenging free 
toxic radicals. (34) Additional and larger 
clinical trials are all that is required to 




Every clinician should be aware of the 
nephrotoxic effect of certain drugs in 
the perioperative period. Nonsteroidal 
anti-inflammatory drugs (NSAIDs) sho-
uld be avoided in patients with hypo-
volemia and sepsis regardless of the 
renal function. (35) These drugs impair 
renal autoregulation by inhibiting pro-
staglandin mediated dilatation of the 
afferent glomerular arteriole resulting in 
decreased renal blood flow in the state 
of systemic vasoconstriction. They also 
can cause acute interstitial nephritis. 
Angiotensin converting enzyme inhibi-
tor (ACEi) and angotensin II receptor 
blockers (ARBs) should be excluded on 
the day of surgery since they have no 
renal protective benefits in the periope-
rative period and can cause refractory 
hypotension. (36) These drugs prevent 
the local action of bradykinins, which 
cause a constriction of the efferent glo-
merular arteriole and in this way mainta-
ins glomerular perfusion pressure in the 
renal autoregulation process. Certain 
antibiotics, such as aminoglycosides, 
which in high concentrations are res-
ponsible for renal tubular toxicity and 
require drug levels monitoring, or those 
that cause acute interstitial nephritis, 
such as penicillins, cephalosporins 
and flouroquinolones, should also be 
avoided. (26) Likewise, minimizing the 
requirements of diagnostic and thera-
peutic procedures with an intravenous 
contrast agent application is also advi-
sable. 
Conclusion
Perioperative AKI is a serious complica-
tion and should be promptly recognized. 
It has implications on both short-term 
and long-term morbidity and mortality. 
(37) Every patient should therefore be 
preoperatively submitted to the General 
Surgery AKI Risk Index scoring system. 
(1) Having an ideal renal biomarker with 
high specificity and sensitivity would 
be helpful. Although this marker still 
does not exist, some new potential bio-
markers are in the experimental stage 
and require validation in larger studies 
prior to application in the clinical prac-
tise. Hence, we should always bear in 
mind that patients with AKI have three 
possible outcomes: return to baseline 
renal function, development of chro-
nic kidney disease in the previously 
normal kidney, or progression of the 
pre-existing chronic kidney disease. 
Every delay in the AKI recognition and 
treatment, as well not applying risk 
stratification and preventive measures, 
can therefore change the outcome and 
quality of life of patients who develop 
AKI after major surgery.
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